6533b82ffe1ef96bd1294fa7

RESEARCH PRODUCT

Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2

Frederick J. EhlertNigel J. M. BirdsallErnst MutschlerHeinz KilbingerGünter LambrechtNeil M. NathansonRoy D. SchwarzSophie J. BradleyRichard M. EglenChristian C. FelderDavid M. ThalR. A. John ChallissRudolf HammerAndrew B. TobinJürgen WessArthur ChristopoulosCeline ValantNoel J. BuckleyFred MitchelsonDavid BrownChris Langmead

subject

BradycardiaAtropineChemistryPilocarpineMuscarinic acetylcholine receptormedicinemedicine.symptomPharmacologyMuscarinic AgentsAcetylcholineEndogenous agonistmedicine.drugAcetylcholine receptor

description

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates. I

yearjournalcountryeditionlanguage
2021-06-25IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/f2/2021.2